

World Journal of *Neurology*

World J Neurol 2013 March 28; 3(1): 1-3



Editorial Board

2011-2015

The *World Journal of Neurology* Editorial Board consists of 324 members, representing a team of worldwide experts in neurology. They are from 38 countries, including Australia (7), Austria (3), Belgium (3), Brazil (4), Canada (7), China (26), Croatia (1), Cuba (1), Cyprus (1), Czech Republic (1), Denmark (2), Egypt (4), Finland (1), France (2), Germany (17), Greece (5), Hungary (3), India (8), Iran (1), Israel (4), Italy (34), Japan (16), Mexico (5), Morocco (1), New Zealand (2), Nigeria (1), Poland (1), Portugal (2), Saudi Arabia (2), Singapore (6), Slovakia (1), South Korea (3), Spain (13), Switzerland (1), Thailand (3), Turkey (7), United Kingdom (12), and United States (113).

EDITOR-IN-CHIEF

Felipe Fregni, *Boston*
Vincenzo Solfrizzi, *Bari*

GUEST EDITORIAL BOARD MEMBERS

Fang-Chia Chang, *Taipei*
Chun-Chuan Chen, *Taoyuan*
San-Yuan Huang, *Taipei*
Suh-Hang Hank Juo, *Kaohsiung City*
Hsien-Yuan Lane, *Taichung*
Ching-Po Lin, *Taipei*
Hung-Chuan Pan, *Taichung*
Bing-wen Soong, *Taipei*
Kuo-Chen Wei, *Taichung*
Sheng-Nan Wu, *Tainan*

MEMBERS OF THE EDITORIAL BOARD



Australia

Roy G Beran, *Sydney*
Lucette Cysique, *Sydney*
John Gardiner, *Sydney*
Manuel B Graeber, *Sydney*
Xu-Feng Huang, *Wollongong*
George Damion Mellick, *Brisbane*
Sarah Spencer, *Victoria*



Austria

Andreas Gruber, *Vienna*
Joerg Kraus, *Salzburg*
Gerlig Widmann, *Anichstr*



Belgium

Anna C Jansen, *Brussels*

Steve Majerus, *Liege*
Rik RC Vandenberghe, *Leuven*



Brazil

Monica L Andersen, *São Paulo*
Elisa Brietzke, *São Paulo*
Paulo A Lotufo, *São Paulo*
Marcelo Rodrigues Masruha, *São Paulo*



Canada

Dave Ellemberg, *Montreal*
Shirley Fecteau, *Quebec*
Adel Gabriel, *Calgary*
Bernard Le Foll, *Toronto*
Laura-Ann Petitto, *Scarborough*
Mubeen Rafay, *Winnipeg*
José M Trigo, *Toronto*



China

Hui-Sheng Chen, *ShenYang*
Mei-Chun Cheung, *Hong Kong*
Wong Kwok Chu, *Hong Kong*
Wan Feng, *Wuhan*
Zhang Hao, *Shanghai*
De-Wen Hu, *Changsha*
Vincent Lai, *Hong Kong*
Xiao-Li Li, *Beijing*
Jian-Min Liu, *Shanghai*
Jun Liu, *Guangzhou*
Xiang-Dong Tang, *Chengdu*
Peng-Fei Yang, *Shanghai*
Xiang Zhang, *Xi'an*
Yan Zhang, *Beijing*
Zhi-Ren Zhang, *Chongqing*
Jin-Xia Zhu, *Beijing*



Croatia

Nela Pivac, *Zagreb*



Cuba

Elena R Cuspineda Bravo, *Habana*



Cyprus

Kyproula Christodoulou, *Nicosia*



Czech Republic

Robert Mikulik, *Brno*



Denmark

Hong-You Ge, *Aalborg*
Peter Johannsen, *Copenhagen*



Egypt

Sherifa Ahmad Hamed, *Dayton*
Taha M Mahmoud, *Zagazig*
Ahmed A K Abdel Razek, *Mansoura*
Sahar N Saleem, *Cairo*



Finland

Seppo Antero Kahkonen, *Helsinki*

**France**

Julien Dauguet, *Orsay*
Cyril Goudet, *Cardonville*

**Germany**

Boldizsar Czeh, *Munich*
Hans-Peter Hartung, *Dusseldorf*
Jens Hauelsen, *Ilmenau*
Dirk M Hermann, *Essen*
Raimund Kleiser, *Linz*
Ulrich Muller, *Giessen*
Walter Paulus, *Gottingen*
Nikolaus Plesnila, *Munich*
Marc Röllinghoff, *Landsberg*
Jens Schittenhelm, *Tuebingen*
Jens Schmidt, *Gottingen*
Rudiger Seitz, *Dusseldorf*
Thomas Straube, *Jena*
Philipp A Thomann, *Heidelberg*
Johannes U V Thome, *Rostock*
Marcus Michael Unger, *Marburg*
Wolfgang Wick, *Heidelberg*

**Greece**

Constantoyannis Constantine, *Patras*
Kostas n Fountas, *Larissa*
Savas Grigoriadis, *Thessaloniki*
Ioannis N Mavridis, *Athens*
George Ntaios, *Larissa*

**Hungary**

Daniel Bereczki, *Budapest*
Xenia Gonda, *Budapest*
Norbert Kovacs, *Pecs*

**India**

Ravindra Kumar Garg, *Lucknow*
Ravi Gupta, *Dehradun*
Birendra Nath Mallick, *New Delhi*
Balraj Mittal, *Lucknow*
Hitesh N Modi, *Ahmedabad*
Mona Ragothaman, *Bangalore*
TN Sathyaprabha, *Bangalore*
Shirley Anne Telles, *Haridwar*

**Iran**

Seyyed Amirhossein Fazeli, *Gorgan*

**Israel**

Dimitrios M Karussis, *Jerusalem*
Asher Ornoy, *Hebrew*
Abraham Weizman, *Tikva*
Perla Werner, *Haifa*

**Italy**

Alberto Albanese, *Milan*
Claudia Altamura, *Rome*
Valeria Barresi, *Messina*
Emanuela Bartoccioni, *Rome*
Gabriella Bottini, *Milan*
Paolo Brambilla, *Udine*
Alfonso Cerase, *Siena*
Polezzi David, *Padova*
Luigi De Gennaro, *Rome*
Stefano Diciotti, *Florence*
Marina Fanin, *Padova*
Michele Ferrara, *L'Aquila*
Daniele Focosi, *Pisa*
Daniela Galimberti, *Milan*
Valentina Garibotto, *Geneva*
Marco Leonardi, *Bologna*
Maria Liguori, *Mangone*
Laura Mandelli, *Bologna*
Gianvito Martino, *Milan*
Giovanni Martinotti, *Rome*
Marianna Mazza, *Rome*
Antonio Orlacchio, *Rome*
Maurizio Paciaroni, *Perugia*
Marco Paoloni, *Rome*
Bernardo Perfetti, *Cheiti*
Alessandro Pezzini, *Brescia*
Gianfranco Puoti, *Naples*
Nilo Riva, *Milan*
Paolo Maria Rossini, *Rome*
Andrea Serino, *Bologna*
Gianfranco Spalletta, *Rome*
Fabrizio Stocchi, *Rome*
Pasquale Striano, *Genova*

**Japan**

Wataru Araki, *Tokyo*
Katsutoshi Furukawa, *Sendai*
Masafumi Ihara, *Kyoto*
Yuichi Inoue, *Tokyo*
Hiroschi Kadotani, *Kyoto*
Kazutaka Kobayashi, *Tokyo*
Yoshihiro Kokubo, *Suita*
Ryuichi Morishita, *Suita*
Tetsu Niwa, *Yokohama*
Katsunori Nonogaki, *Sendai*
Kunihiro Sakuma, *Aichi*
Katsuya Satoh, *Nagasaki*
Atsuyoshi Shimada, *Aichi*
Hiroschi Takahashi, *Tottori*
Naoyuki Takeuchi, *Sendai*
Kanato Yamagata, *Tokyo*

**Mexico**

Agnes Fleury, *Tlalpan*
Daniel San Juan, *Mexico City*
Julio Sotelo, *Mexico City*
Teresa Corona Vázquez, *Tlalpan*
Rodrigo Ramos Zuniga, *Guadalajara Jalisco*

**Morocco**

Samir Ahboucha, *Marrakesh*

**New Zealand**

Juan J Canales, *Christchurch*
Valery Feigin, *Auckland*

**Nigeria**

Mayowa O Owolabi, *Ibadan*

**Poland**

Pawel Piotr Liberski, *Lodz*

**Portugal**

Nuno Martins Marques Canas, *Lisbon*
Isaura Ferreira Tavares, *Porto*

**Saudi Arabia**

Ahmed S BaHammam, *Riyadh*
Essam A Elgamal, *Riyadh*

**Singapore**

Justin HG Dauwels, *Singapore*
Steven Graham, *Singapore*
Charanjit Kaur, *Singapore*
Vijay K Sharma, *Singapore*
Feng-Ru Tang, *Singapore*
Philip Lin Kiat Yap, *Singapore*

**Slovakia**

Peter Valkovič, *Bratislava*

**South Korea**

Ji Soo Kim, *Gyeonggi-do*
Myung Sik Lee, *Seoul*
Kyoungso Suk, *Daegu*

**Spain**

Adria Arboix, *Barcelona*
Pedro Emilio Bermejo, *Madrid*
Ramon Cacabelos, *Coruna*
Isidro Ferrer, *Hospitalet de Llobregat*
Jesús A García-Sevilla, *Palma de Mallorca*
Bernardo Hontanilla, *Pamplona*
Esteban Pena Llamas, *Madrid*
Fernando Maestu, *Madrid*
Arturo Mangas, *Salamanca*
German Moris, *Gijon*
Jordi Perez-Tur, *Madrid*
Javier SCastresana, *Pamplona*
José M Trigo, *Toronto*

**Switzerland**

Marcel Arnold, *Bern*



Thailand

Suparek Janjarasjitt, *Ubon Ratchathani*
Panitha Jindahra, *Bangkok*
Kittipan Rerkasem, *Chiang Mai*



Turkey

Ayşe Aralasmak, *Istanbul*
İsin Baral-Kulaksızoglu, *Istanbul*
Cengiz Cokluk, *Samsun*
Saygın Salih Eker, *Bursa*
Ateş Kadioglu, *Istanbul*
Suleyman Kaplan, *Samsun*
Rifat Nuri Sener, *Izmir*



United Kingdom

Zubair Ahmed, *Birmingham*
Chris John Bushe, *Basingstoke*
Andrea Eugenio Cavanna, *London*
White Gables, *Norwich*
Valentina Gallo, *London*
Sanjay Kumar, *Birmingham*
Tarik F Massoud, *Cambridge*
Mike Modo, *London*
Mario Alfredo Parra, *Edinburgh*
Camillo Porcaro, *Newcastle*
Annette Sterr, *Surrey*
Jan Stochl, *Cambridge*



United States

Herve Abdi, *Dallas*
Abhishek Agrawal, *New York*
Abass Alavi, *Philadelphia*
Quincy J Almeida, *Waterloo*
Alfredo Ardila, *Miami*
Carmel Armon, *Springfield*
Andrew D Barreto, *Houston*
Raymond T Bartus, *San Diego*
Archit Bhatt, *East Lansing*
Margit L Bleecker, *Baltimore*
Anna-Liisa Brownell, *Charlestown*
Ignazio Cali, *Cleveland*

Maren Carbon-Correll, *Manhasset*
Rudolph J Castellani, *Baltimore*
Carlos Cepeda, *Los Angeles*
Munmun Chattopadhyay, *Ann Arbor*
Rivka R Colen, *Boston*
James R Connor, *Hershey*
Li Cui, *Little Rock*
Yuri P Danilov, *Madison*
Mukeshwar Dhamala, *Atlanta*
David M Diamond, *Tampa*
David William Dodick, *Phoenix*
Richard I Doty, *Pennsylvania*
Christopher L Drake, *Detroit*
Timothy Q Duongthpd, *San Antonio*
Sherif M Elbasiouny, *Chicago*
Adam S Fleisher, *San Diego*
Robert Folmer, *Portland*
Majid Fotuhi, *Baltimore*
Dheeraj Gandhi, *Baltimore*
Yu-Lin Ge, *New York*
Hugo Geerts, *Berwyn*
Alexandros L Georgiadis, *Minneapolis*
Srikanth Givvmani, *Louisville*
Charles G Gross, *Princeton*
George T Grossberg, *Saint Louis*
Zhen He, *Jefferson*
Ming-Xiong Huang, *San Diego*
Siros Jafarian, *North Vancouver*
Xiangning Jiang, *San Francisco*
Peter B Kang, *Boston*
Junghoon Kim, *Elkins Park*
David C Knight, *Birmingham*
Kennith F Layton, *Dallas*
Andrew G Lee, *Houston*
Walter S Lesley, *Temple*
David Sigmund Liebeskind, *Los Angeles*
Tianming Liu, *Athens*
Yahia M Lodi, *New York*
Edythe D London, *Los Angeles*
Jean-Pierre Louboutin, *Philadelphia*
Hanzhang Lu, *Dallas*
Kenneth Maiese, *Newark*
Silva Markovic-Plese, *Chapel Hill*
Marlon Stephen Mathews, *Orange*
Yousef Mohammad, *Chicago*
Amanda J Myers, *Miami*
Josef Novotny Jr, *Pittsburgh*
Arne M Nystuen, *Omaha*
Darin T Okuda, *Phoenix*
Wei-hong Pan, *Baton Rouge*

Juliann M Paolicchi, *Nashville*
Spyros Papapetropoulos, *Santa Ana*
Sergio Paradiso, *Iowa City*
Paul Park, *Ann Arbor*
Hemant A Parmar, *Ann Arbor*
George Perry, *San Antonio*
Marc Nicholas Potenza, *New Haven*
Yonglin Pu, *Chicago*
Haifa Qiao, *Tallahassee*
Liya Qiao, *Richmond*
Ralph Rahme, *Cincinnati*
Amit Ray, *New York*
Catherine M Roe, *Missouri*
Theodore H Schwartz, *New York*
Robert J Schwartzman, *Philadelphia*
Thomas F Scott, *Pittsburgh*
Souvik Sen, *Columbia*
Khema Sharma, *Miami*
Li Shen, *Indianapolis*
Gabriel A Silva, *La Jolla*
Elsayed Z Soliman, *Winston Salem*
Joshua Goh Oon Soo, *Baltimore*
Ashok Srinivasan, *Ann Arbor*
Massoud Stephane, *Minneapolis*
Shu-Wei Sun, *Loma Linda*
Emi Takahashi, *Boston*
Thomas Thannickal, *North Hills*
Timothy Adam Thrasher, *Houston*
Guochuan Emil Tsai, *Torrance*
Vassiliy Tsytsarev, *Fairfax*
Tanya Nadine Turan, *Charleston*
Neetu Tyagi, *Louisville*
Denise A Valenti, *Boston*
Piero Verro, *Sacramento*
Marcela Votruba, *Cardiff*
Jian Wang, *Baltimore*
Kenneth L Weiss, *Jackson*
Harry T Whelan, *Milwaukee*
Keith D White, *Gainesville*
Peter Widdess-Walsh, *Livingston*
Zhongcong Xie, *Boston*
Midori Anne Yenari, *San Francisco*
Albert J Yoo, *Boston*
Robert J Young, *New York*
Brad Evan Zacharia, *New York*
T Thomas Zacharia, *Hershey*
Gabriel Zada, *Los Angeles*
Haoqian Zhang, *San Francisco*
Ming Zhang, *Philadelphia*
Yun Zhou, *Baltimore*



CASE REPORT

- 1 Hashimoto's encephalopathy presenting as acute cognitive decline in an elderly male

Aryal MR, Giri S, Mainali NR, Smith K

APPENDIX I-V Instructions to authors

ABOUT COVER Editorial Board Member of *World Journal of Neurology*, Ming-Xiong Huang, PhD, Professor and Associate Director of MEG, Radiology Imaging Laboratory, Department of Radiology, University of California, San Diego, 3510 Dunhill Street, San Diego, CA 92121, United States

AIM AND SCOPE *World Journal of Neurology (World J Neurol, WJN)*, online ISSN 2218-6212, DOI: 10.5316) is a peer-reviewed open access academic journal that aims to guide clinical practice and improve diagnostic and therapeutic skills of clinicians.

WJN covers topics concerning neuro-oncology, electroneurophysiology, cerebrovascular diseases, epilepsy, cognitive impairment, myopathy and peripheral neuropathy, degenerative diseases, infectious diseases, demyelinating diseases, immunological diseases, genetic/metabolic diseases, affective disorders, headaches, sleep disorders, interventional neuroradiology, minimally invasive therapy, rehabilitation, diagnostic imaging, evidence-based medicine, epidemiology and nursing. Priority publication will be given to articles concerning diagnosis and treatment of neurological diseases. The following aspects are covered: Clinical diagnosis, laboratory diagnosis, differential diagnosis, imaging tests, pathological diagnosis, molecular biological diagnosis, immunological diagnosis, genetic diagnosis, functional diagnostics, and physical diagnosis; and comprehensive therapy, drug therapy, surgical therapy, interventional treatment, minimally invasive therapy, and robot-assisted therapy.

We encourage authors to submit their manuscripts to *WJN*. We will give priority to manuscripts that are supported by major national and international foundations and those that are of great basic and clinical significance.

INDEXING/ABSTRACTING *World Journal of Neurology* is now indexed in Digital Object Identifier.

FLYLEAF I-III Editorial Board

EDITORS FOR THIS ISSUE Responsible Assistant Editor: *Shuai Ma* Responsible Science Editor: *Ling-Ling Wen*
 Responsible Electronic Editor: *Xiao-Mei Zheng*
 Proofing Editor-in-Chief: *Lian-Sheng Ma*

NAME OF JOURNAL
World Journal of Neurology

ISSN
 ISSN 2218-6212 (online)

LAUNCH DATE
 December 28, 2011

FREQUENCY
 Quarterly

EDITOR-IN-CHIEF
Felipe Fregni, MD, PhD, MPH, Associate Professor, Department of Physical Medicine and Rehabilitation, Spaulding Rehabilitation Hospital, Harvard Medical School, 125 Nashua St. Room 725, Boston, MA 02114, United States

Vincenzo Solfrizzi, MD, PhD, Professor, Department of Internal Medicine, Immunology and Infectious Diseases, Section of Geriatric Medicine-Memory

Unit, University of Bari, P.zza G. Cesare, 11, 70124 Bari, Italy

EDITORIAL OFFICE
 Jin-Lei Wang, Director
 Xiu-Xia Song, Vice Director
World Journal of Neurology
 Room 903, Building D, Ocean International Center, No. 62 Dongsihuan Zhonglu, Chaoyang District, Beijing 100025, China
 Telephone: +86-10-85381891
 Fax: +86-10-85381893
 E-mail: wjneuro@wjnet.com
<http://www.wjnet.com>

PUBLISHER
 Baishideng Publishing Group Co., Limited
 Flat C, 23/F, Lucky Plaza,
 315-321 Lockhart Road, Wan Chai,
 Hong Kong, China
 Fax: +852-6555-7188
 Telephone: +852-3177-9906
 E-mail: bpgoffice@wjnet.com
<http://www.wjnet.com>

PUBLICATION DATE
 March 28, 2013

COPYRIGHT
 © 2013 Baishideng. Articles published by this Open Access journal are distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license.

SPECIAL STATEMENT
 All articles published in this journal represent the viewpoints of the authors except where indicated otherwise.

INSTRUCTIONS TO AUTHORS
 Full instructions are available online at http://www.wjnet.com/2218-6212/g_info_20100722173918.htm

ONLINE SUBMISSION
<http://www.wjnet.com/esp/>

Hashimoto's encephalopathy presenting as acute cognitive decline in an elderly male

Madan Raj Aryal, Smith Giri, Naba Raj Mainali, Karen Smith

Madan Raj Aryal, Naba Raj Mainali, Karen Smith, Department of Medicine, Reading Health System, West Reading, PA 19611, United States

Smith Giri, Department of Medicine, Tribhuvan University Teaching Hospital, Maharajgunj, Kathmandu 44600, Nepal

Author contributions: Aryal MR and Mainali NR wrote the primary draft of the manuscript; Giri S edited the primary draft; Smith K was the attending physician who reviewed and edited the final manuscript.

Correspondence to: Madan Raj Aryal, MD, Department of Medicine, Reading Health System, 6th avenue and spruce street, West Reading, PA 19611, United States. aryal.madan@gmail.com
Telephone: +1-917-7563767 Fax: +1-917-7563767

Received: January 2, 2013 Revised: February 11, 2013

Accepted: March 26, 2013

Published online: March 28, 2013

Core tip: Hashimoto's encephalopathy is a rare form of reversible encephalopathy characterized by the presence of anti-thyroid antibodies in serum and/or cerebrospinal fluid. We suggest that an assessment of thyroid antibodies should be included in anyone presenting with acute cognitive decline in the absence of alternative explanation.

Aryal MR, Giri S, Mainali NR, Smith K. Hashimoto's encephalopathy presenting as acute cognitive decline in an elderly male. *World J Neurol* 2013; 3(1): 1-3 Available from: URL: <http://www.wjgnet.com/2218-6212/full/v3/i1/1.htm> DOI: <http://dx.doi.org/10.5316/wjn.v3.i1.1>

Abstract

Hashimoto's encephalopathy (HE) is a rare form of reversible encephalopathy characterized by the presence of anti-thyroid antibodies in serum and/or cerebrospinal fluid. The syndrome is more common in women and the presentation varies considerably. Here, we report a case of an elderly male with a history of Hashimoto's thyroiditis, presenting with acute cognitive decline. A diagnosis of HE was established based on the presence of anti-thyroid antibodies in the serum, diffuse electroencephalography changes and lack of an alternative explanation. The patient promptly responded to steroids and was discharged on the 8th day of admission. We suggest that an assessment of thyroid antibodies should be included in anyone presenting with acute cognitive decline in the absence of alternative explanation.

© 2013 Baishideng. All rights reserved.

Key words: Hashimoto's encephalopathy; Hashimoto's thyroiditis; Anti-thyroid antibodies; Electroencephalography; Steroids; Cognitive decline; Immunosuppressants

INTRODUCTION

Hashimoto's encephalopathy (HE) is a rare, poorly understood neurological syndrome associated with autoimmune thyroiditis. The disease has an estimated prevalence of 2.1/100 000^[1]. Since, it was first described by Brain *et al* in 1966, about 113 cases have been reported till date^[2]. HE has a widely variable clinical spectrum with both acute and indolent forms^[3]. However, cognitive decline and seizures are the commonest manifestations of this disease^[2]. Most reported cases are females and the disease seems to peak in the fifth and sixth decades of life^[2]. In this report, we present a case of an elderly male who presented to us with acute cognitive decline along with a brief review of literature. We emphasize the importance of an early diagnosis of this potentially treatable condition.

CASE REPORT

A 76-year-old Caucasian male with history of Hashimoto's thyroiditis presented with complaints of feeling unwell and confusion for 1 d. His past medical history was significant for atrial fibrillation, diabetes mellitus, hyperten-

sion, hyperlipidemia, Hypothyroidism due to Hashimoto's thyroiditis and gastroesophageal reflux disease. He was diagnosed with Hashimoto's thyroiditis 8 years back based on the presence of anti-thyroid peroxidase antibody, anti-thyroglobulin antibody and biopsy showing diffuse lymphocytic and plasma cell infiltration. He was currently taking levothyroxine 100 mcg daily. His other medications included metoprolol and omeprazole. He denied chills, fever, shortness of breath, chest pain and seizure activity. On examination, he was afebrile with a heart rate of 150/min and blood pressure of 78/44 mmHg. He was not oriented to time, place and person. However, no focal neurological deficits were appreciated. The patient did not have a past history of similar symptoms. In the emergency room, he was noted to be in atrial fibrillation with a rapid ventricular response. He was then intubated for his unstable vital signs and transferred to the intensive care unit.

Lab work done revealed CBC and Electrolytes to be normal. Urine drug screen was negative. Cultures of blood and urine were negative. His chest X-ray and arterial blood gas were normal. Cortisol level was within normal range. Electrocardiogram revealed atrial fibrillation but no evidence of recent onset ischemia. Cardiac enzymes were normal. Computed tomography of the chest, abdomen and magnetic resonance imaging (MRI) of the head were negative. Toxicology screen for acetaminophen and alcohol were negative. Cerebrospinal fluid (CSF) analysis was normal except for elevated protein at 229 mg/dL. CSF cultures failed to grow any organisms. Viral serology done for HSV, St. Louis and West Nile virus were negative. TSH was elevated at 11.4 IU/mL (normal 0.3-5 IU/mL). Also, anti-thyroid peroxidase antibody was elevated at 128 IU/mL (normal: < 34 IU/mL). However, T3 and T4 were 1.1 ng/mL (normal: 0.9-1.8 ng/mL) and 7.8 µg/dL (normal: 5.5-11.6 µg/dL), respectively. Anti-thyroglobulin antibody was elevated at 554 IU/mL (Normal: 0-60 IU/mL). Electroencephalography (EEG) revealed continuous slow and generalized pattern along with focal spikes and triphasic waves.

In the intensive care unit, blood pressure was maintained with intravenous fluids and dopamine. Over the next 24 h, the patient had improvement in hemodynamics and was in normal sinus rhythm and was successfully extubated. However he continued to be encephalopathic for the next 36 h. Neurological examination revealed generalized stupor, gross disorientation to time, place and person and absence of any focal neurological deficits.

Our initial impression of hypoxic encephalopathy was refuted because the patient continued to be confused even after the stabilization of hemodynamics. This led us to search for other causes of his confusion. Central nervous system infection was ruled out by normal CSF findings. Any, organic lesion of the brain and stroke were ruled out with normal MRI findings. Other metabolic causes were ruled out with normal urine drug screen, liver and renal function tests. With the background of an abnormal EEG, elevated thyroid antibodies, elevated

CSF protein, unrevealing cerebral MRI and lack of an alternative diagnoses, we suspected the patient to have HE and started the patient on 200 mg of intravenous hydrocortisone every 8 h for 2 d. He showed significant improvement and completely recovered with no neurological deficits in the next 48 h. He was then switched to 60 mg of oral hydrocortisone to be tapered over 3 wk and was discharged on 8th day of admission. At the time of discharge the patient was alert and well oriented to time, place and person. The patient is undergoing regular follow up and is in good health since then.

DISCUSSION

HE is an under-diagnosed, steroid-responsive, reversible encephalopathy associated with high titers of serum anti-thyroid antibodies^[3]. The pathogenesis of this condition is still unclear and is unlikely to be directly related to thyroiditis indicated by the presence of thyroid peroxidase antibodies^[3]. As a result, some authors have advocated a change of nomenclature to "steroid-responsive encephalopathy associated with autoimmune thyroiditis"^[4]. Recent reports have suggested it to be a result of reversible cerebral inflammation mediated by an autoimmune mechanism^[5].

In contradiction to our case, most reported cases are females, probably reflecting the fact that autoimmune thyroiditis has a female predilection^[3]. Castillo *et al*^[5] suggested that as much as 70% of cases of HE are females. The age at presentation is widely variable with an average of 50 years and reported cases ranging from 2 to 84 years^[3,6]. The commonest age group, however, is in the fifth and sixth decades of life^[2]. Our patient, being 76 years of age, is one of the oldest patients reported to have this disease.

The clinical features of HE are known to be extremely variable. It may present acutely, with episodes of cerebral ischemia, seizures and psychosis, or it may present as an indolent form with depression, myoclonus, tremors, cognitive decline and fluctuations in the level of consciousness^[2]. Acute cognitive impairment, as seen in our case, is one of the commonest forms of presentation, seen in approximately 36% of the cases^[4].

The exact pathogenesis for HE is unknown. Autopsy/brain biopsy samples of affected patients have shown perivascular lymphocytic infiltrates, predominantly of the T-cell type, in the meninges and the brain parenchyma^[5]. This, along with the female preponderance of the disease and a good response to steroids, favors an autoimmune etiology. As the majority of patients are euthyroid at presentation, the disease does not seem necessarily to be related to the level of thyroid hormones. Current evidence does not show that antithyroid antibodies interact with neuronal tissues and their levels are not related with the severity of the disease or the response to treatment either^[2]. However, a recent study has shown that thyroid antibodies are associated with other anti-neuronal antibodies such as antibodies to voltage-gated potassium channel and N methyl-D-aspartate receptor; suggesting a possible pathogenetic mechanism of this condition^[7].

Most of the cases of HE are affected by Hashimoto's thyroiditis, which was also seen in our patient^[8]. However, about 19% of cases have Grave's disease, suggesting that the disease is not associated exclusively with Hashimoto's thyroiditis, but also with other autoimmune thyroid diseases^[2]. Most patients have normal levels of thyroid hormones; a few are hypothyroid or hyperthyroid at presentation. Our patient was euthyroid at presentation.

There is no universally agreed diagnostic criterion for HE^[9]. One such criteria suggested by Peschen-Rosin *et al*^[10] encompasses unexplained occurrence of certain neurological symptoms along with three conditions among which are: abnormal EEG, elevated thyroid antibodies, elevated CSF protein, excellent response to steroids and unrevealing cerebral MRI. In our case, a diagnosis of HE was conveniently made by fulfilling this criteria along with an absence of an alternative diagnosis. Elevated levels of anti-thyroid antibodies are the most consistent finding in reported cases, which could be considered as a hallmark of HE^[11]. However, there is no evidence that these antibodies affect neuronal function and their levels do not correlate with the severity of the disease or the response to treatment^[2,12]. Similarly, abnormal EEG findings are found in up to 98% of cases; the most common abnormality being a generalized slowing of waves, as in our case^[13]. Meanwhile, the role of brain imaging in the diagnosis is primarily to exclude other diagnostic possibilities. Brain imaging is normal in as many as 50% of cases, and abnormal findings include cerebral atrophy, diffuse white matter changes and meningeal enhancement^[6]. In our patient, the role of brain imaging (MRI) was to rule out other alternative diagnoses.

HE is known to be one of the reversible forms of encephalopathy. Corticosteroids are the preferred medications for treatment, effective in as much as 98% of the cases^[12]. In our case, rapid clinical improvement was seen following the use of steroids. Other immunosuppressants such as methotrexate, azathioprine, and cyclophosphamide have also been reported to treat HE successfully^[6]. However, sometimes, HE might not be completely cured and relapses may occur. Nevertheless, the overall prognosis remains optimistic, as long as patients receive adequate treatment^[6].

In summary, HE is a rare form of reversible encephalopathy, occurring in patients with or without overt thyroid disease. The presentations are varied but diffuse cognitive decline is a common manifestation. Considering the myriad of neurologic manifestations of this disease and a lack of well-defined diagnostic criteria, the disease appears to be under-diagnosed. Nevertheless, a timely diagnosis

is crucial as it is often completely reversible. Anyone presenting with rapidly progressive cognitive dysfunction with or without a history of thyroid disease, should be considered for a possibility of HE and assessed for the presence of antithyroid antibodies.

REFERENCES

- 1 **Nolte KW**, Unbehaun A, Sieker H, Kloss TM, Paulus W. Hashimoto encephalopathy: a brainstem vasculitis? *Neurology* 2000; **54**: 769-770 [PMID: 10680826]
- 2 **de Holanda NC**, de Lima DD, Cavalcanti TB, Lucena CS, Bandeira F. Hashimoto's encephalopathy: systematic review of the literature and an additional case. *J Neuropsychiatry Clin Neurosci* 2011; **23**: 384-390 [PMID: 22231308 DOI: 10.1176/appi.neuropsych.23.4.384]
- 3 **Erol I**, Saygi S, Alehan F. Hashimoto's encephalopathy in children and adolescents. *Pediatr Neurol* 2011; **45**: 420-422 [PMID: 22115010 DOI: 10.1016/j.pediatrneurol.2011.09.010]
- 4 **Ferracci F**, Carnevale A. The neurological disorder associated with thyroid autoimmunity. *J Neurol* 2006; **253**: 975-984 [PMID: 16786216]
- 5 **Castillo P**, Woodruff B, Caselli R, Vernino S, Lucchinetti C, Swanson J, Noseworthy J, Aksamit A, Carter J, Sirven J, Hunder G, Fatourechi V, Mokri B, Drubach D, Pittock S, Lennon V, Boeve B. Steroid-responsive encephalopathy associated with autoimmune thyroiditis. *Arch Neurol* 2006; **63**: 197-202 [PMID: 16476807]
- 6 **Zhao W**, Li J, Wang J, Guo Y, Tuo H, Kang Z, Jiang B, Wang R, Wang D. A case of Hashimoto encephalopathy: clinical manifestation, imaging, pathology, treatment, and prognosis. *Neurologist* 2011; **17**: 141-143 [PMID: 21532381 DOI: 10.1097/NRL.0b013e3182173341]
- 7 **Tüzün E**, Erdağ E, Durmus H, Brenner T, Türkoglu R, Kürtüncü M, Lang B, Akman-Demir G, Eraksoy M, Vincent A. Autoantibodies to neuronal surface antigens in thyroid antibody-positive and -negative limbic encephalitis. *Neurol India* 2011; **59**: 47-50 [PMID: 21339658 DOI: 10.4103/0028-3886.76857]
- 8 **Tamagno G**, Federspil G, Murialdo G. Clinical and diagnostic aspects of encephalopathy associated with autoimmune thyroid disease (or Hashimoto's encephalopathy). *Intern Emerg Med* 2006; **1**: 15-23 [PMID: 16941808]
- 9 **Tang Y**, Xing Y, Lin MT, Zhang J, Jia J. Hashimoto's encephalopathy cases: Chinese experience. *BMC Neurol* 2012; **12**: 60 [PMID: 22827897 DOI: 10.1186/1471-2377-12-60]
- 10 **Peschen-Rosin R**, Schabet M, Dichgans J. Manifestation of Hashimoto's encephalopathy years before onset of thyroid disease. *Eur Neurol* 1999; **41**: 79-84 [PMID: 10023109]
- 11 **Mijajlovic M**, Mirkovic M, Dackovic J, Zidverc-Trajkovic J, Sternic N. Clinical manifestations, diagnostic criteria and therapy of Hashimoto's encephalopathy: report of two cases. *J Neurol Sci* 2010; **288**: 194-196 [PMID: 19846119 DOI: 10.1016/j.jns.2009.09.030]
- 12 **Schiess N**, Pardo CA. Hashimoto's encephalopathy. *Ann N Y Acad Sci* 2008; **1142**: 254-265 [PMID: 18990131]
- 13 **Chong JY**, Rowland LP, Utiger RD. Hashimoto encephalopathy: syndrome or myth? *Arch Neurol* 2003; **60**: 164-171 [PMID: 12580699]

P- Reviewers Araki W, Zhang M, Bartoccioni E
S- Editor Song XX **L- Editor** A **E- Editor** Zheng XM



GENERAL INFORMATION

World Journal of Neurology (*World J Neurol*, *WJN*, online ISSN 2218-6212, DOI: 10.5316) is a peer-reviewed open access (OA) academic journal that aims to guide clinical practice and improve diagnostic and therapeutic skills of clinicians.

Aim and scope

WJN covers topics concerning neuro-oncology, electroneurophysiology, cerebrovascular diseases, epilepsy, cognitive impairment, myopathy and peripheral neuropathy, degenerative diseases, infectious diseases, demyelinating diseases, immunological diseases, genetic/metabolic diseases, affective disorders, headaches, sleep disorders, interventional neuroradiology, minimally invasive therapy, rehabilitation, diagnostic imaging, evidence-based medicine, epidemiology and nursing. The current columns of *WJN* include editorial, frontier, diagnostic advances, therapeutics advances, field of vision, mini-reviews, review, topic highlight, medical ethics, original articles, case report, clinical case conference (Clinicopathological conference), and autobiography. Priority publication will be given to articles concerning diagnosis and treatment of neurological diseases. The following aspects are covered: Clinical diagnosis, laboratory diagnosis, differential diagnosis, imaging tests, pathological diagnosis, molecular biological diagnosis, immunological diagnosis, genetic diagnosis, functional diagnostics, and physical diagnosis; and comprehensive therapy, drug therapy, surgical therapy, interventional treatment, minimally invasive therapy, and robot-assisted therapy.

We encourage authors to submit their manuscripts to *WJN*. We will give priority to manuscripts that are supported by major national and international foundations and those that are of great basic and clinical significance.

WJN is edited and published by Baishideng Publishing Group (BPG). BPG has a strong professional editorial team composed of science editors, language editors and electronic editors. BPG currently publishes 42 OA clinical medical journals, including 41 in English, has a total of 15 471 editorial board members or peer reviewers, and is a world first-class publisher.

Columns

The columns in the issues of *WJN* will include: (1) Editorial: The editorial board members are invited to make comments on an important topic in their field in terms of its current research status and future directions to lead the development of this discipline; (2) Frontier: The editorial board members are invited to select a highly cited cutting-edge original paper of his/her own to summarize major findings, the problems that have been resolved and remain to be resolved, and future research directions to help readers understand his/her important academic point of view and future research directions in the field; (3) Diagnostic Advances: The editorial board members are invited to write high-quality diagnostic advances in their field to improve the diagnostic skills of readers. The topic covers general clinical diagnosis, differential diagnosis, pathological diagnosis, laboratory diagnosis, imaging diagnosis, endoscopic diagnosis, biotechnological diagnosis, functional diagnosis, and physical diagnosis; (4) Therapeutics Advances: The editorial board members are invited to write high-quality therapeutic advances in their field to help improve the therapeutic skills of readers. The topic covers medication therapy, psychotherapy, physical therapy, replacement therapy, interventional therapy, minimally invasive therapy, endo-

scopic therapy, transplantation therapy, and surgical therapy; (5) Field of Vision: The editorial board members are invited to write commentaries on classic articles, hot topic articles, or latest articles to keep readers at the forefront of research and increase their levels of clinical research. Classic articles refer to papers that are included in Web of Knowledge and have received a large number of citations (ranking in the top 1%) after being published for more than years, reflecting the quality and impact of papers. Hot topic articles refer to papers that are included in Web of Knowledge and have received a large number of citations after being published for no more than 2 years, reflecting cutting-edge trends in scientific research. Latest articles refer to the latest published high-quality papers that are included in PubMed, reflecting the latest research trends. These commentary articles should focus on the status quo of research, the most important research topics, the problems that have now been resolved and remain to be resolved, and future research directions. Basic information about the article to be commented (including authors, article title, journal name, year, volume, and inclusive page numbers); (6) Minireviews: The editorial board members are invited to write short reviews on recent advances and trends in research of molecular biology, genomics, and related cutting-edge technologies to provide readers with the latest knowledge and help improve their diagnostic and therapeutic skills; (7) Review: To make a systematic review to focus on the status quo of research, the most important research topics, the problems that have now been resolved and remain to be resolved, and future research directions; (8) Topic Highlight: The editorial board members are invited to write a series of articles (7-10 articles) to comment and discuss a hot topic to help improve the diagnostic and therapeutic skills of readers; (9) Medical Ethics: The editorial board members are invited to write articles about medical ethics to increase readers' knowledge of medical ethics. The topic covers international ethics guidelines, animal studies, clinical trials, organ transplantation, etc.; (10) Clinical Case Conference or Clinicopathological Conference: The editorial board members are invited to contribute high-quality clinical case conference; (11) Original Articles: To report innovative and original findings in neurology; (12) Brief Articles: To briefly report the novel and innovative findings in neurology; (13) Meta-Analysis: To evaluate the clinical effectiveness in neurology by using data from two or more randomised control trials; (14) Case Report: To report a rare or typical case; (15) Letters to the Editor: To discuss and make reply to the contributions published in *WJN*, or to introduce and comment on a controversial issue of general interest; (16) Book Reviews: To introduce and comment on quality monographs of neurology; and (17) Autobiography: The editorial board members are invited to write their autobiography to provide readers with stories of success or failure in their scientific research career. The topic covers their basic personal information and information about when they started doing research work, where and how they did research work, what they have achieved, and their lessons from success or failure.

Name of journal

World Journal of Neurology

ISSN

ISSN 2218-6212 (online)

Launch date

December 28, 2011

Instructions to authors

Frequency

Quarterly

Editor-in-Chief

Felipe Fregni, MD, PhD, MPH, Associate Professor, Department of Physical Medicine and Rehabilitation, Spaulding Rehabilitation Hospital, Harvard Medical School, Room 725, 125 Nashua St. Boston, MA 02114, United States

Vincenzo Solfrizzi, MD, PhD, Professor, Department of Internal Medicine, Immunology and Infectious Diseases, Section of Geriatric Medicine-Memory Unit, University of Bari, P.zza G. Cesare, 11, 70124 Bari, Italy

Editorial office

Jin-Lei Wang, Director
Xiu-Xia Song, Vice Director
World Journal of Neurology
Room 903, Building D, Ocean International Center,
No. 62 Dongsihuan Zhonglu, Chaoyang District,
Beijing 100025, China
Telephone: +86-10-85381891
Fax: +86-10-85381893
E-mail: wjneuro@wjnet.com
<http://www.wjnet.com>

Publisher

Baishideng Publishing Group Co., Limited
Flat C, 23/F, Lucky Plaza, 315-321 Lockhart Road,
Wan Chai, Hong Kong, China
Telephone: +852-58042046
Fax: +852-31158812
E-mail: bpgoffice@wjnet.com
<http://www.wjnet.com>

Production center

Beijing Baishideng BioMed Scientific Co., Limited
Room 903, Building D, Ocean International Center,
No. 62 Dongsihuan Zhonglu, Chaoyang District,
Beijing 100025, China
Telephone: +86-10-85381892
Fax: +86-10-85381893

Representative office

USA Office
8226 Regency Drive,
Pleasanton, CA 94588-3144, United States

Instructions to authors

Full instructions are available online at http://www.wjnet.com/2218-6212/g_info_20100722173918.htm.

Indexed and Abstracted in

Digital Object Identifier.

SPECIAL STATEMENT

All articles published in this journal represent the viewpoints of the authors except where indicated otherwise.

Biostatistical editing

Statistical review is performed after peer review. We invite an expert in Biomedical Statistics to evaluate the statistical method used in the paper, including *t*-test (group or paired comparisons), chi-squared test, Riddit, probit, logit, regression (linear, curvilinear, or stepwise), correlation, analysis of variance, analysis of covariance, *etc.* The reviewing points include: (1) Statistical methods should be described when they are used to verify the results; (2) Whether the statistical techniques are suitable or correct; (3) Only homogeneous data can be averaged. Standard deviations are preferred to standard errors. Give the number of observations and subjects (*n*). Losses

in observations, such as drop-outs from the study should be reported; (4) Values such as ED50, LD50, IC50 should have their 95% confidence limits calculated and compared by weighted probit analysis (Bliss and Finney); and (5) The word 'significantly' should be replaced by its synonyms (if it indicates extent) or the *P* value (if it indicates statistical significance).

Conflict-of-interest statement

In the interests of transparency and to help reviewers assess any potential bias, *WJN* requires authors of all papers to declare any competing commercial, personal, political, intellectual, or religious interests in relation to the submitted work. Referees are also asked to indicate any potential conflict they might have reviewing a particular paper. Before submitting, authors are suggested to read "Uniform Requirements for Manuscripts Submitted to Biomedical Journals: Ethical Considerations in the Conduct and Reporting of Research: Conflicts of Interest" from International Committee of Medical Journal Editors (ICMJE), which is available at: http://www.icmje.org/ethical_4conflicts.html.

Sample wording: [Name of individual] has received fees for serving as a speaker, a consultant and an advisory board member for [names of organizations], and has received research funding from [names of organization]. [Name of individual] is an employee of [name of organization]. [Name of individual] owns stocks and shares in [name of organization]. [Name of individual] owns patent [patent identification and brief description].

Statement of informed consent

Manuscripts should contain a statement to the effect that all human studies have been reviewed by the appropriate ethics committee or it should be stated clearly in the text that all persons gave their informed consent prior to their inclusion in the study. Details that might disclose the identity of the subjects under study should be omitted. Authors should also draw attention to the Code of Ethics of the World Medical Association (Declaration of Helsinki, 1964, as revised in 2004).

Statement of human and animal rights

When reporting the results from experiments, authors should follow the highest standards and the trial should conform to Good Clinical Practice (for example, US Food and Drug Administration Good Clinical Practice in FDA-Regulated Clinical Trials; UK Medicines Research Council Guidelines for Good Clinical Practice in Clinical Trials) and/or the World Medical Association Declaration of Helsinki. Generally, we suggest authors follow the lead investigator's national standard. If doubt exists whether the research was conducted in accordance with the above standards, the authors must explain the rationale for their approach and demonstrate that the institutional review body explicitly approved the doubtful aspects of the study.

Before submitting, authors should make their study approved by the relevant research ethics committee or institutional review board. If human participants were involved, manuscripts must be accompanied by a statement that the experiments were undertaken with the understanding and appropriate informed consent of each. Any personal item or information will not be published without explicit consents from the involved patients. If experimental animals were used, the materials and methods (experimental procedures) section must clearly indicate that appropriate measures were taken to minimize pain or discomfort, and details of animal care should be provided.

SUBMISSION OF MANUSCRIPTS

Manuscripts should be typed in 1.5 line spacing and 12 pt. Book Antiqua with ample margins. Number all pages consecutively, and start each of the following sections on a new page: Title Page, Abstract, Introduction, Materials and Methods, Results, Discussion, Acknowledgements, References, Tables, Figures, and Figure Legends. Neither the editors nor the publisher are responsible for the opinions expressed by contributors. Manuscripts formally accepted for publication become the permanent property of Baishideng Publishing Group Co., Limited, and may not be reproduced by any means, in whole or in part, without the written permission of both the authors and the publisher. We reserve the right to copy-

edit and put onto our website accepted manuscripts. Authors should follow the relevant guidelines for the care and use of laboratory animals of their institution or national animal welfare committee. For the sake of transparency in regard to the performance and reporting of clinical trials, we endorse the policy of the ICMJE to refuse to publish papers on clinical trial results if the trial was not recorded in a publicly-accessible registry at its outset. The only register now available, to our knowledge, is <http://www.clinicaltrials.gov> sponsored by the United States National Library of Medicine and we encourage all potential contributors to register with it. However, in the case that other registers become available you will be duly notified. A letter of recommendation from each author's organization should be provided with the contributed article to ensure the privacy and secrecy of research is protected.

Authors should retain one copy of the text, tables, photographs and illustrations because rejected manuscripts will not be returned to the author(s) and the editors will not be responsible for loss or damage to photographs and illustrations sustained during mailing.

Online submissions

Manuscripts should be submitted through the Online Submission System at: <http://www.wjgnet.com/esps/>. Authors are highly recommended to consult the ONLINE INSTRUCTIONS TO AUTHORS (http://www.wjgnet.com/2218-6212/g_info_20100722173918.htm) before attempting to submit online. For assistance, authors encountering problems with the Online Submission System may send an email describing the problem to wjneuro@wjgnet.com, or by telephone: +86-10-85381892. If you submit your manuscript online, do not make a postal contribution. Repeated online submission for the same manuscript is strictly prohibited.

MANUSCRIPT PREPARATION

All contributions should be written in English. All articles must be submitted using word-processing software. All submissions must be typed in 1.5 line spacing and 12 pt. Book Antiqua with ample margins. Style should conform to our house format. Required information for each of the manuscript sections is as follows:

Title page

Title: Title should be less than 12 words.

Running title: A short running title of less than 6 words should be provided.

Authorship: Authorship credit should be in accordance with the standard proposed by ICMJE, based on (1) substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data; (2) drafting the article or revising it critically for important intellectual content; and (3) final approval of the version to be published. Authors should meet conditions 1, 2, and 3.

Institution: Author names should be given first, then the complete name of institution, city, province and postcode. For example, Xu-Chen Zhang, Li-Xin Mei, Department of Pathology, Chengde Medical College, Chengde 067000, Hebei Province, China. One author may be represented from two institutions, for example, George Sgourakis, Department of General, Visceral, and Transplantation Surgery, Essen 45122, Germany; George Sgourakis, 2nd Surgical Department, Korgialenio-Benakio Red Cross Hospital, Athens 15451, Greece

Author contributions: The format of this section should be: Author contributions: Wang CL and Liang L contributed equally to this work; Wang CL, Liang L, Fu JF, Zou CC, Hong F and Wu XM designed the research; Wang CL, Zou CC, Hong F and Wu XM performed the research; Xue JZ and Lu JR contributed new reagents/analytic tools; Wang CL, Liang L and Fu JF analyzed the data; and Wang CL, Liang L and Fu JF wrote the paper.

Supportive foundations: The complete name and number of supportive foundations should be provided, *e.g.*, Supported by National Natural Science Foundation of China, No. 30224801

Correspondence to: Only one corresponding address should be provided. Author names should be given first, then author title, affiliation, the complete name of institution, city, postcode, province, country, and email. All the letters in the email should be in lower case. A space interval should be inserted between country name and email address. For example, Montgomery Bissell, MD, Professor of Medicine, Chief, Liver Center, Gastroenterology Division, University of California, Box 0538, San Francisco, CA 94143, United States. montgomery.bissell@ucsf.edu

Telephone and fax: Telephone and fax should consist of +, country number, district number and telephone or fax number, *e.g.*, Telephone: +86-10-85381892 Fax: +86-10-85381893

Peer reviewers: All articles received are subject to peer review. Normally, three experts are invited for each article. Decision on acceptance is made only when at least two experts recommend publication of an article. All peer-reviewers are acknowledged on Express Submission and Peer-review System website.

Abstract

There are unstructured abstracts (no less than 200 words) and structured abstracts. The specific requirements for structured abstracts are as follows:

An informative, structured abstract should accompany each manuscript. Abstracts of original contributions should be structured into the following sections: AIM (no more than 20 words; Only the purpose of the study should be included. Please write the Aim in the form of "To investigate/study/..."), METHODS (no less than 140 words for Original Articles; and no less than 80 words for Brief Articles), RESULTS (no less than 150 words for Original Articles and no less than 120 words for Brief Articles; You should present *P* values where appropriate and must provide relevant data to illustrate how they were obtained, *e.g.*, 6.92 ± 3.86 vs 3.61 ± 1.67 , $P < 0.001$), and CONCLUSION (no more than 26 words).

Key words

Please list 5-10 key words, selected mainly from *Index Medicus*, which reflect the content of the study.

Core tip

Please write a summary of less than 100 words to outline the most innovative and important arguments and core contents in your paper to attract readers.

Text

For articles of these sections, original articles and brief articles, the main text should be structured into the following sections: INTRODUCTION, MATERIALS AND METHODS, RESULTS and DISCUSSION, and should include appropriate Figures and Tables. Data should be presented in the main text or in Figures and Tables, but not in both.

Illustrations

Figures should be numbered as 1, 2, 3, *etc.*, and mentioned clearly in the main text. Provide a brief title for each figure on a separate page. Detailed legends should not be provided under the figures. This part should be added into the text where the figures are applicable. Keeping all elements compiled is necessary in line-art image. Scale bars should be used rather than magnification factors, with the length of the bar defined in the legend rather than on the bar itself. File names should identify the figure and panel. Avoid layering type directly over shaded or textured areas. Please use uniform legends for the same subjects. For example: Figure 1 Pathological changes in atrophic gastritis after treatment. A: ...; B: ...; C: ...; D: ...; E: ...; F: ...; G: ... *etc.* It is our principle to publish high resolution-figures for the E-versions.

Instructions to authors

Tables

Three-line tables should be numbered 1, 2, 3, *etc.*, and mentioned clearly in the main text. Provide a brief title for each table. Detailed legends should not be included under tables, but rather added into the text where applicable. The information should complement, but not duplicate the text. Use one horizontal line under the title, a second under column heads, and a third below the Table, above any footnotes. Vertical and italic lines should be omitted.

Notes in tables and illustrations

Data that are not statistically significant should not be noted. ^a*P* < 0.05, ^b*P* < 0.01 should be noted (*P* > 0.05 should not be noted). If there are other series of *P* values, ^c*P* < 0.05 and ^d*P* < 0.01 are used. A third series of *P* values can be expressed as ^e*P* < 0.05 and ^f*P* < 0.01. Other notes in tables or under illustrations should be expressed as ¹F, ²F, ³F; or sometimes as other symbols with a superscript (Arabic numerals) in the upper left corner. In a multi-curve illustration, each curve should be labeled with ●, ○, ■, □, ▲, △, *etc.*, in a certain sequence.

Acknowledgments

Brief acknowledgments of persons who have made genuine contributions to the manuscript and who endorse the data and conclusions should be included. Authors are responsible for obtaining written permission to use any copyrighted text and/or illustrations.

REFERENCES

Coding system

The author should number the references in Arabic numerals according to the citation order in the text. Put reference numbers in square brackets in superscript at the end of citation content or after the cited author's name. For citation content which is part of the narration, the coding number and square brackets should be typeset normally. For example, "Crohn's disease (CD) is associated with increased intestinal permeability^[1,2]". If references are cited directly in the text, they should be put together within the text, for example, "From references^[19,22-24], we know that..."

When the authors write the references, please ensure that the order in text is the same as in the references section, and also ensure the spelling accuracy of the first author's name. Do not list the same citation twice.

PMID and DOI

Please provide PubMed citation numbers to the reference list, *e.g.*, PMID and DOI, which can be found at <http://www.ncbi.nlm.nih.gov/sites/entrez?db=pubmed> and <http://www.crossref.org/SimpleTextQuery/>, respectively. The numbers will be used in E-version of this journal.

Style for journal references

Authors: the name of the first author should be typed in bold-faced letters. The family name of all authors should be typed with the initial letter capitalized, followed by their abbreviated first and middle initials. (For example, Lian-Sheng Ma is abbreviated as Ma LS, Bo-Rong Pan as Pan BR). The title of the cited article and italicized journal title (journal title should be in its abbreviated form as shown in PubMed), publication date, volume number (in black), start page, and end page [PMID: 11819634 DOI: 10.3748/wjg.13.5396].

Style for book references

Authors: the name of the first author should be typed in bold-faced letters. The surname of all authors should be typed with the initial letter capitalized, followed by their abbreviated middle and first initials. (For example, Lian-Sheng Ma is abbreviated as Ma LS, Bo-Rong Pan as Pan BR) Book title. Publication number. Publication place: Publication press, Year: start page and end page.

Format

Journals

English journal article (list all authors and include the PMID where applicable)

1 Jung EM, Clevert DA, Schreyer AG, Schmitt S, Rennert J,

Kubler R, Feuerbach S, Jung F. Evaluation of quantitative contrast harmonic imaging to assess malignancy of liver tumors: A prospective controlled two-center study. *World J Gastroenterol* 2007; **13**: 6356-6364 [PMID: 18081224 DOI: 10.3748/wjg.13.6356]

Chinese journal article (list all authors and include the PMID where applicable)

2 Lin GZ, Wang XZ, Wang P, Lin J, Yang FD. Immunologic effect of Jianpi Yishen decoction in treatment of Pixu-diarhoea. *Shijie Huaren Xiaobua Zazhi* 1999; **7**: 285-287

In press

3 Tian D, Araki H, Stahl E, Bergelson J, Kreitman M. Signature of balancing selection in Arabidopsis. *Proc Natl Acad Sci USA* 2006; In press

Organization as author

4 Diabetes Prevention Program Research Group. Hypertension, insulin, and proinsulin in participants with impaired glucose tolerance. *Hypertension* 2002; **40**: 679-686 [PMID: 12411462 PMID: 2516377 DOI: 10.1161/01.HYP.0000035706.28494.09]

Both personal authors and an organization as author

5 Vallancien G, Emberton M, Harving N, van Moorselaar RJ; Alf-One Study Group. Sexual dysfunction in 1, 274 European men suffering from lower urinary tract symptoms. *J Urol* 2003; **169**: 2257-2261 [PMID: 12771764 DOI: 10.1097/01.ju.0000067940.76090.73]

No author given

6 21st century heart solution may have a sting in the tail. *BMJ* 2002; **325**: 184 [PMID: 12142303 DOI: 10.1136/bmj.325.7357.184]

Volume with supplement

7 Geraud G, Spierings EL, Keywood C. Tolerability and safety of frovatriptan with short- and long-term use for treatment of migraine and in comparison with sumatriptan. *Headache* 2002; **42** Suppl 2: S93-99 [PMID: 12028325 DOI: 10.1046/j.1526-4610.42.s2.7.x]

Issue with no volume

8 Banit DM, Kaufer H, Hartford JM. Intraoperative frozen section analysis in revision total joint arthroplasty. *Clin Orthop Relat Res* 2002; (**401**): 230-238 [PMID: 12151900 DOI: 10.1097/00003086-200208000-00026]

No volume or issue

9 Outreach: Bringing HIV-positive individuals into care. *HRS-A Careaction* 2002; 1-6 [PMID: 12154804]

Books

Personal author(s)

10 Sherlock S, Dooley J. Diseases of the liver and biliary system. 9th ed. Oxford: Blackwell Sci Pub, 1993: 258-296

Chapter in a book (list all authors)

11 Lam SK. Academic investigator's perspectives of medical treatment for peptic ulcer. In: Swabb EA, Azabo S. Ulcer disease: investigation and basis for therapy. New York: Marcel Dekker, 1991: 431-450

Author(s) and editor(s)

12 Breedlove GK, Schorfheide AM. Adolescent pregnancy. 2nd ed. Wiczorek RR, editor. White Plains (NY): March of Dimes Education Services, 2001: 20-34

Conference proceedings

13 Harnden P, Joffe JK, Jones WG, editors. Germ cell tumours V. Proceedings of the 5th Germ cell tumours Conference; 2001 Sep 13-15; Leeds, UK. New York: Springer, 2002: 30-56

Conference paper

14 Christensen S, Oppacher F. An analysis of Koza's computational effort statistic for genetic programming. In: Foster JA, Lutton E, Miller J, Ryan C, Tettamanzi AG, editors. Genetic programming. EuroGP 2002: Proceedings of the 5th European Conference on Genetic Programming; 2002 Apr 3-5; Kinsdale, Ireland. Berlin: Springer, 2002: 182-191

Electronic journal (list all authors)

15 Morse SS. Factors in the emergence of infectious diseases.

Emerg Infect Dis serial online, 1995-01-03, cited 1996-06-05; 1(1): 24 screens. Available from: URL: <http://www.cdc.gov/ncidod/eid/index.htm>

Patent (list all authors)

16 **Pagedas AC**, inventor; Ancel Surgical R&D Inc., assignee. Flexible endoscopic grasping and cutting device and positioning tool assembly. United States patent US 20020103498. 2002 Aug 1

Statistical data

Write as mean \pm SD or mean \pm SE.

Statistical expression

Express *t* test as *t* (in italics), *F* test as *F* (in italics), chi square test as χ^2 (in Greek), related coefficient as *r* (in italics), degree of freedom as ν (in Greek), sample number as *n* (in italics), and probability as *P* (in italics).

Units

Use SI units. For example: body mass, *m* (B) = 78 kg; blood pressure, *p* (B) = 16.2/12.3 kPa; incubation time, *t* (incubation) = 96 h; blood glucose concentration, *c* (glucose) 6.4 \pm 2.1 mmol/L; blood CEA mass concentration, *p* (CEA) = 8.6 24.5 μ g/L; CO₂ volume fraction, 50 mL/L CO₂, not 5% CO₂; likewise for 40 g/L formaldehyde, not 10% formalin; and mass fraction, 8 ng/g, *etc.* Arabic numerals such as 23, 243, 641 should be read 23243641.

The format for how to accurately write common units and quantum numbers can be found at: http://www.wjgnet.com/2218-6212/g_info_20100723222255.htm.

Abbreviations

Standard abbreviations should be defined in the abstract and on first mention in the text. In general, terms should not be abbreviated unless they are used repeatedly and the abbreviation is helpful to the reader. Permissible abbreviations are listed in Units, Symbols and Abbreviations: A Guide for Biological and Medical Editors and Authors (Ed. Baron DN, 1988) published by The Royal Society of Medicine, London. Certain commonly used abbreviations, such as DNA, RNA, HIV, LD50, PCR, HBV, ECG, WBC, RBC, CT, ESR, CSF, IgG, ELISA, PBS, ATP, EDTA, mAb, can be used directly without further explanation.

Italics

Quantities: *t* time or temperature, *c* concentration, *A* area, *l* length, *m* mass, *V* volume.

Genotypes: *gyrA*, *arg 1*, *c myc*, *c fos*, *etc.*

Restriction enzymes: *EcoRI*, *HindI*, *BamHI*, *Kho I*, *Kpn I*, *etc.*

Biology: *H. pylori*, *E. coli*, *etc.*

Examples for paper writing

All types of articles' writing style and requirement will be found in the link: <http://www.wjgnet.com/esps/NavigationInfo.aspx?id=15>

RESUBMISSION OF THE REVISED MANUSCRIPTS

Authors must revise their manuscript carefully according to the revision policies of Baishideng Publishing Group Co., Limited. The revised version, along with the signed copyright transfer agreement, responses to the reviewers, and English language Grade A certificate (for non-native speakers of English), should be submitted to the online system *via* the link contained in the e-mail sent by the editor. If you have any questions about the revision, please send e-mail to esps@wjgnet.com.

Language evaluation

The language of a manuscript will be graded before it is sent for revision. (1) Grade A: priority publishing; (2) Grade B: minor language polishing; (3) Grade C: a great deal of language polishing needed; and (4) Grade D: rejected. Revised articles should reach Grade A.

Copyright assignment form

Please download a Copyright assignment form from http://www.wjgnet.com/2218-6212/g_info_20100723222139.htm.

Responses to reviewers

Please revise your article according to the comments/suggestions provided by the reviewers. The format for responses to the reviewers' comments can be found at: http://www.wjgnet.com/2218-6212/g_info_20100723222041.htm.

Proof of financial support

For papers supported by a foundation, authors should provide a copy of the approval document and serial number of the foundation.

Links to documents related to the manuscript

WJN will be initiating a platform to promote dynamic interactions between the editors, peer reviewers, readers and authors. After a manuscript is published online, links to the PDF version of the submitted manuscript, the peer-reviewers' report and the revised manuscript will be put on-line. Readers can make comments on the peer reviewer's report, authors' responses to peer reviewers, and the revised manuscript. We hope that authors will benefit from this feedback and be able to revise the manuscript accordingly in a timely manner.

Publication fee

WJN is an international, peer-reviewed, OA online journal. Articles published by this journal are distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium and format, provided the original work is properly cited. The use is non-commercial and is otherwise in compliance with the license. Authors of accepted articles must pay a publication fee. Publication fee: 600 USD per article. All invited articles are published free of charge.



百世登

Baishideng®

Published by **Baishideng Publishing Group Co., Limited**

Flat C, 23/F., Lucky Plaza, 315-321 Lockhart Road,

Wan Chai, Hong Kong, China

Fax: +852-31158812

Telephone: +852-58042046

E-mail: bpgoffice@wjgnet.com

<http://www.wjgnet.com>

